Phase II study of high‐dose tamoxifen (NSC‐180973) in patients with disseminated malignant melanoma

Edward T. Creagan, James N. Ingle, David L. Ahmann, Stephanie J. Green

Research output: Contribution to journalArticle

19 Scopus citations


Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.

Original languageEnglish (US)
Pages (from-to)1353-1354
Number of pages2
Issue number7
StatePublished - Apr 1 1982


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this